Type 1 diabetes in a melanoma patient treated with ipilimumab after nivolumab

J Dermatol. 2018 Oct;45(10):e289-e290. doi: 10.1111/1346-8138.14331. Epub 2018 Apr 18.

Authors

Toshikazu Omodaka¹, Yukiko Kiniwa¹, Yuki Sato¹, Manabu Suwa¹, Misato Sato¹, Tomohiko Yamaguchi², Ai Sato², Tomomi Miyake¹, Ryuhei Okuyama¹

Affiliations

¹ Department of Dermatology, Shinshu University School of Medicine, Matsumoto, Japan.
² Department of Endocrinology, Metabolism and Diabetes, Shinshu University School of Medicine, Matsumoto, Japan.

PMID: 29667767
DOI: 10.1111/1346-8138.14331

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antineoplastic Agents, Immunological / administration & dosage
Antineoplastic Agents, Immunological / adverse effects*
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Blood Glucose / analysis
Diabetes Mellitus, Type 1 / blood
Diabetes Mellitus, Type 1 / chemically induced*
Diabetes Mellitus, Type 1 / diagnosis
Diabetes Mellitus, Type 1 / immunology
Female
Humans
Ipilimumab / administration & dosage
Ipilimumab / adverse effects*
Melanoma / drug therapy
Middle Aged
Nivolumab / administration & dosage
Nivolumab / adverse effects*
Skin Neoplasms / drug therapy

Substances

Antineoplastic Agents, Immunological
Blood Glucose
Ipilimumab
Nivolumab